Landmark ECOG-ACRIN ENDURANCE Study Co-Authored by International Myeloma Foundation Leaders Provides Evidence for Optimal Duration of Maintenance Therapy

Phase 3positivePositive

AI Analysis

Summary

The randomized Phase III ENDURANCE (E1A11) trial results were published in the New England Journal of Medicine, providing evidence for optimal duration of maintenance therapy in myeloma treatment. The study was designed and conducted by ECOG-ACRIN Cancer Research Group with co-authorship from International Myeloma Foundation leaders.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

NCT ID

E1A11

Outcome Details

Phase III ENDURANCE (E1A11) trial results published in New England Journal of Medicine, providing evidence for optimal duration of maintenance therapy in myeloma

Importance:6/10

Sentiment:

0.70

myelomamaintenance therapyECOG-ACRINrandomized prospective trialpublication

Related Companies

$ISCO

Read the original article

Published by GlobeNewswire Clinical Studies on July 15, 2026 9:00 PM

Read Original